Resumen

TALAVERA, María L et al. Hipertensión pulmonar grave reversible asociada al uso de dasatinib en un paciente con leucemia mieloide crónica. Rev. amer. med. respiratoria [online]. 2013, vol.13, n.4, pp.239-242. ISSN 1852-236X.

Pulmonary arterial hypertension is a rare disease that is characterized by a progressive increase in vascular pulmonary resistance, chronic right ventricle failure and premature death. Pulmonary arterial hypertension can be either idiopathic or associated to other conditions such as portal hypertension, human immunodeficiency virus, connective tissue diseases, congenital systemic-to-pulmonary shunts or associated to different drugs/toxins. Encouraging progress has been made by targeting the main vasoproliferative aspects of the disease. Tyrosine kinase inhibitors (TKI) are promising emerging therapeutics. Imatinib, a selective TKI approved for the treatment of chronic myeloid leukaemia, has demonstrated some efficacy in treating pulmonary arterial hypertension in a phase II study. However, the TKI dasatinib, also approved for therapy of chronic myeloid leukaemia, has been linked to reversible pulmonary arterial hypertension and right ventricular failure, with pleural effusion, suggesting the possibility of drug-related pulmonary arterial hypertension.

Palabras clave : Pulmonary arterial hypertension; Reversible; Drug toxicity; Dasatinib.

        · resumen en Español     · texto en Español     · Español ( pdf )